First World Congress on Therapies against Obesity: Perspectives for
Pharmaceutical and Natural Products
Paris Anti-Obesity Therapies 2006
Maison de la Chimie – Paris - France
May 18-19, 2006
Organization commitee : Dr Marvin Edeas, Dr Bernard Schmitt, Pr Alain Geloën, Dr Paul Goetz
Thursday May 18 2006
8:30 Registration and Welcome Address
Dr Marvin Edeas, President of the French Society of Antioxidants, Paris, France
9:00 Economic Impact of Anti-Obesity Drugs
 What marketshare do anti-obesity drugs have in France, in Europe and world wide?
 What are the latest trends in the anti-obesity drug market?
Proposed to Mrs Katia Musitu, IMS Health, London, UK
SESSION 1 : General Presentation of Obesity
9:30 An Overview on Obesity
Obesity, a recently accepted disease
Definition, prevalence, pathogenesis and ethiology of obesity
 Role of genetical factors: mutations in leptin gene, melanocortin 4 receptor gene (MC4R)
and genes involved in pathways regulating body weight, appetite or energy expenditure.
Over-exression of lipin.
 Role of environmental factors: dietary trends, sedentary lifestyle, decreases in physical
activity
Proposed to Peter Kopelman, University of London, London, UK
10:15 Break
10:45 What are the Obesity Associated Diseases?
Type 2 Diabetis mellitus
Cardio-vascular diseases : hypertension, dyslipidemia, atherosclerosis, stroke
Cancer, Osteoarthritis, Sleep apnoea, depression and unfertility...
11:15 Obesity in children
Prevalence and diagnosis
What are the risks for obese children ?
 Effects on growth and maturation
 Psychological impacts
 Diabets and cardio-vascular diseases: what repercussions once adult?
Prevention and management of obesity in children: what tools, what strategies?
Proposed to Pr Rüdiger von Kries, Ludwig Maximillians University, Munich, Germany
11:45 Obesity in animals
What are the animals concerned by obesity?
What are the differences or similarities with obesity in humans?
What are the different ways to manage this problem?
Proposed to Christophe Blanckaert, Veterinary Clinic Les Margats, Boulogne sur Mer, France
12:30 Lunch
SESSION 2: What are the strategies used to prevent and/or treat obesity ?
14:00 Targeting the Energy Intake and Expenditure Balance
How can energy intake be reduced? Anorexigenic and orexigenic signals
How can energy expenditure be increased? Acting on thermogenesis
Proposed to Pr Stephen O’Rahilly, University of Cambridge, Cambridge, UK
14:30 Targeting the Lipid and Carbohydrate Metabolism
Inhibition of fatty acids absorption
Inhibition of adipogenesis and fat storage
Stimulation of enzymes involved in lipolysis
Proposed to Dr Paul Burn, Bayer Health Care, West Haven, USA
15:00 Oral presentations selected upon abstract submission
15:30 Break
16:00 Current Pharmacotherapies and New Drugs in Developpment
Appetite suppressors: example of Sibutramine. Mechanism of action, efficiency and side effects.
Metabolism modificators: example of Orlistat. Mechanism of action, efficiency and side effects.
New drugs in developpment: Axokine, Rimonabant and Bupropion SR.
Proposed to Pr Olivier Ziegler,Hospital of Nancy, Toul, France
16:30 Bariatric surgery
What are the different kind of bariatric surgeries? Gastroplasty, gastric bypass, biliopancreatic
diversion, gastric banding
What efficiency for what risk? Clinical data
Proposed to Dr Jérôme Dargent, Policlinic of Rillieux, Rillieux-le-pape, France
17:00 End of the Day
Friday May 19 2006
SESSION 3: New Targets for Therapies against Obesity
9:00 Interesting Molecular Targets: the Peroxisome Proliferator-Activated Receptors
(PPARs)
What is the connection between glucide and lipid metabolism
The different isoforms and their respective rôle in lipid and glucose homeostasis
Future directions for new therapies against obesity: example of PPAR-δ agonists
Proposed to Pr Staels, University of Lille 2, Lille, France
9:45 New Targets Rising from RNAi
What is RNAi technology?
What are the different in vitro and in vivo steps to indentify a potential traget ?
What are the new targets identified by RNAi technology for obesity?
Proposed to Pr Michael Czech, University of Massachusets, Worcester, USA
10:15 Break
10:45 Inflammation and Obesity: a new field for therapy?
What is the link between inflammation and obesity?
Inflammatory cytokines and oxidative stress: what role for antioxidant molecules?
What are the emerging pathways for the developpment of new therapies against obesity?
Proposed Dr Alain Géloën, University of Lyon 1, Lyon, France
11:25 Role of Mitochondria and Uncoupling Proteins in Obesity and Insulin Resistance
Mitochondria and thermogenesis
Uncoupling proteins and insulin resistance
Uncouplig proteins: a new target to treat obesity?
Proposed to Pr Daniel Ricquier, NeckerHospital, Paris, France
12:00 Oral presentations selected upon abstract submission
12 :30 Lunch
SESSION 4: Latest Advances on Natural Ingredients and Alternative
Therapeutics against Obesity
14:00 Conjugated Linoleic Acid (CLA): which isomer, toxicity and clinical data
Dr Bernard Schmitt, CERN/CHBS, Lorient, France
14:30 Potential Use of Natural Antioxidants in the treatment of Obesity
Inhibition of the oxidative stress vicious circle
How can antioxidants control mitochondria metabolism?
Which antioxidant can we use to treat obesity: green tea extract, lipoic acid, riboflavin and LCarnitine
Dr Marvin Edeas, President of the French Society of Antioxidants, Paris, France
15:00 Natural Appetite Suppressants
What ingredients are acting on Cholecystokinin (CCK) and Glucagon-Lik Peptide 1 (GLP1)?
Results of a new clinical study: efficiency of an original ingredient
Proposed to Sandra Einerhand, Lipid Nutrition, Wormerveer, The Netherlands
15:30 Break
16:00 Update, Toxicity and Clinical Data on Natural Ingredients against Obesity
Green coffee beans, Ephedra, Fenugreek, Garcinia cambodgia, Guarana, Ispaghula, Konjac,
Manganese, Nopal, Apple pectin, Phaseolus vulgaris, Phlorizin, Hieracium pilosella, calcium,
potassium, chitosan.
Proposed to Dr Paul Goetz, Strasbourg, France
16:45 Dietary Supplements for Body-Weight Reduction: a Review
Proposed to Pr Edzard Ernst, University of Exeter and Plymouth, Exeter, UK
17:05 What Are the Latest Innovations in the Anti-Obesity Drug and Natural Ingredients
Field: Presentations by Pharmaceutical Laboratories, Food Supplement Companies,
Cosmetics Companies and Start-Ups (6 minutes to convince)
If you want to present your innovation, please contact us.
17:45 Round Table Discussion
What are the Perspectives for Anti-Obesity Therapies: are Natural Ingredients an
Alternative to Treat Obesity?
(In the Presence of the Scientific Committee)
Anti-Obesity Drugs 2006 Innovation Award
The scientific committee will name the most innovative project upon oral or poster presentation